NEW YORK (GenomeWeb News) – Exact Sciences has submitted the third and final module of its premarket approval application to the US Food and Drug Administration for its Cologuard colorectal cancer screening test, the company said today.
Registering provides access to this and other free content.
Already have an account?Login Now.
Hong Kong is using DNA phenotyping to shame litterers.
A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.
NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.
In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.